• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace@İSÜ
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed | DergiPark
  • PubMed İndeksli Yayınlar Koleksiyonu
  • View Item
  •   DSpace@İSÜ
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed | DergiPark
  • PubMed İndeksli Yayınlar Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects

Thumbnail

View/Open

Tam Metin / Full Text (3.662Mb)

Date

2022

Author

Paskeh, Mahshid Deldar Abad
Mehrabi, Atefeh
Gholami, Mohammad Hossein
Zabolian, Amirhossein
Ranjbar, Ehsan
Zarrabi, Ali

Metadata

Show full item record

Citation

Paskeh, M., Mehrabi, A., Gholami, M. H., Zabolian, A., Ranjbar, E., Saleki, H., Ranjbar, A., Hashemi, M., Ertas, Y. N., Hushmandi, K., Mirzaei, S., Ashrafizadeh, M., Zarrabi, A., & Samarghandian, S. (2021). EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 146, 112532. Advance online publication.

Abstract

Brain tumors are responsible for high mortality and morbidity worldwide. The brain tumor treatment depends on identification of molecular pathways involved in progression and malignancy. Enhancer of zeste homolog 2 (EZH2) has obtained much attention in recent years in field of cancer therapy due to its aberrant expression and capacity in modulating expression of genes by binding to their promoter and affecting methylation status. The present review focuses on EZH2 signaling in brain tumors including glioma, glioblastoma, astrocytoma, ependymomas, medulloblastoma and brain rhabdoid tumors. EZH2 signaling mainly participates in increasing proliferation and invasion of cancer cells. However, in medulloblastoma, EZH2 demonstrates tumor-suppressor activity. Furthermore, EZH2 can regulate response of brain tumors to chemotherapy and radiotherapy. Various molecular pathways can function as upstream mediators of EZH2 in brain tumors including lncRNAs and miRNAs. Owing to its enzymatic activity, EZH2 can bind to promoter of target genes to induce methylation and affects their expression. EZH2 can be considered as an independent prognostic factor in brain tumors that its upregulation provides undesirable prognosis. Both anti-tumor agents and gene therapies such as siRNA have been developed for targeting EZH2 in cancer therapy.

Source

Biomedicine & Pharmacotherapy

Volume

146

URI

https://doi.org/10.1016/j.biopha.2021.112532
https://hdl.handle.net/20.500.12713/2332

Collections

  • Makale Koleksiyonu [33]
  • PubMed İndeksli Yayınlar Koleksiyonu [890]
  • Scopus İndeksli Yayınlar Koleksiyonu [1274]
  • WoS İndeksli Yayınlar Koleksiyonu [1330]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




| Instruction | Guide | Contact |

DSpace@İSÜ

by OpenAIRE
Advanced Search

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypeLanguageDepartmentCategoryPublisherAccess TypeInstitution AuthorThis CollectionBy Issue DateAuthorsTitlesSubjectsTypeLanguageDepartmentCategoryPublisherAccess TypeInstitution Author

My Account

LoginRegister

Statistics

View Google Analytics Statistics

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Guide|| Instruction || Library || İstinye University || OAI-PMH ||

İstinye University, İstanbul, Turkey
If you find any errors in content, please contact:

Creative Commons License
İstinye University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@İSÜ:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.